It is quite reassuring in that when any competitive product is discussed that would go up against B-OM, B-IBD, or Kevetrin and it is analyzed, the IPIX product is heads and shoulders above in terms of ease of delivery and lack of safety issues. I will not comment on the efficacy of each as I am not well versed on the competitive products success rates.

A good example is of the recently mentioned P3 for OM that turns out to indeed be a pill but needs to be kept in the mouth for hours and works for only a very narrow sector of OM sufferers. Another is a pill (Xeljanz) I saw on TV last night for UC that sounded just like what we hope B-IBD becomes, but once they started listing the major health issues it became readily apparent B-UC will be heads and shoulders above this competitive product.

And to think we have only started to scratch the surface of possible B indications and a successful pill formulation for K will throw wide open the doors to what I believe will be a large number of trials where K is a complementary medication to current treatments and will in turn make them more effective and most likely less toxic.

Expecting very good things in April!!!